• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Canadian journal of clinical pharmacology =: Journal canadien de pharmacologie clinique >Safety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation.
【24h】

Safety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation.

机译：替加色罗治疗肠易激综合症或慢性便秘患者的安全性和有效性。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Tegaserod, a 5-HT4 agonist, is effective for treating irritable bowel syndrome and chronic constipation. However, sales of this drug were recently suspended due to concerns about a higher rate of cardiovascular events in patients receiving tegaserod over placebo in clinical trials. Our aim was to review patients in our practice prescribed tegaserod to determine if any of them had suffered a cardiovascular event or other significant adverse effects while on this therapy. Additionally, we attempted to determine the efficacy of tegaserod in clinical practice. Patients with irritable bowel syndrome or chronic constipation in our practice prescribed tegaserod were identified through a search of billing codes and charts reviews. These patients were contacted and questioned about symptoms of cardiovascular events or other adverse events while on tegaserod. The efficacy of this drug was determined by a symptom scale during and after stopping tegaserod. Sufficient data for analysis was retrieved for 51 of 67 patients prescribed tegaserod. Of these, 37 patients (72.5%) experience no adverse events and 14 patients (27.4%) experienced at least one adverse event, including 6 patients (11.8%) with major adverse events (2 patients (3.9%) with atypical chest pain; 4 patients (7.8%) with syncope; and 2 patients (3.9%) who died. One patient died from advanced pancreatic cancer. The other, who had multiple cardiovascular risk factors as well as a previous myocardial infarction, suffered a cardiac arrest 2 days postoperatively following a below knee amputation, and had actually been off tegaserod for 7 days after hospital admission. Patients graded the severity of both abdominal pain and constipation as worse after stopping therapy compared to during therapy (p<0.0002 and p<0.0001, respectively). The risk of cardiovascular events during tegaserod therapy may be increased in patients with other risk factors. However, this drug is effective for treating irritable bowel syndrome and chronic constipation, and might be used in a select patient population with severe symptoms but without other risk factors for cardiovascular events.
机译：Tegaserod是5-HT4激动剂，可有效治疗肠易激综合症和慢性便秘。然而，由于担心在临床试验中接受替加色罗治疗的患者比安慰剂治疗的心血管事件发生率更高，该药物的销售最近被暂停。我们的目的是在我们的处方替加色罗治疗实践中对患者进行检查，以确定他们中的任何患者在此治疗期间是否发生了心血管事件或其他重大不良反应。此外，我们尝试确定替加色罗在临床实践中的功效。通过搜索计费代码和图表评论，可以识别出肠易激综合征或慢性便秘的患者（在我们的实践中使用替加色罗）。在使用替加色罗时，与这些患者接触并询问了心血管事件或其他不良事件的症状。该药物的疗效由停用替加色罗期间和之后的症状量表确定。对于67名处方替加色罗的患者中，有51名获得了足够的分析数据。其中，37例（72.5％）无不良反应，14例（27.4％）至少发生1例不良反应，其中6例（11.8％）有严重不良事件（2例（3.9％））有非典型性胸痛。 4例（7.8％）发生晕厥; 2例（3.9％）死亡;一名患者死于晚期胰腺癌;另一名患有多种心血管危险因素以及先前有心肌梗死的患者在2天后心脏骤停膝关节以下截肢术后，实际上已经入院7天，患者在停止治疗后与治疗期间相比，腹痛和便秘的严重程度被评定为差（分别为p <0.0002和p​​ <0.0001） 。具有其他危险因素的患者，在替加色龙治疗期间发生心血管事件的风险可能会增加，但是，这种药物可有效治疗肠易激综合症和慢性便秘，因此可以选择使用具有严重症状但没有其他心血管事件危险因素的患者人群。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号